PLANT ADVANCED TECHNOLOGIES (ALPAT.PA) Stock Fundamental Analysis
Europe - Euronext Paris - EPA:ALPAT - FR0010785790 - Common Stock
7.68 EUR
-0.1 (-1.29%)
ALPAT gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 86 industry peers in the Biotechnology industry. ALPAT may be in some trouble as it scores bad on both profitability and health. ALPAT has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
- ALPAT had positive earnings in the past year.
- In multiple years ALPAT reported negative net income over the last 5 years.
- The reported operating cash flow has been mixed in the past 5 years: ALPAT reported negative operating cash flow in multiple years.
1.2 Ratios
- With a decent Return On Assets value of 2.00%, ALPAT is doing good in the industry, outperforming 77.91% of the companies in the same industry.
- The Return On Equity of ALPAT (3.43%) is better than 79.07% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2% | ||
| ROE | 3.43% | ||
| ROIC | N/A |
ROA(3y)1.25%
ROA(5y)-1.47%
ROE(3y)2.03%
ROE(5y)-3.1%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- With an excellent Profit Margin value of 34.16%, ALPAT belongs to the best of the industry, outperforming 90.70% of the companies in the same industry.
- The Gross Margin of ALPAT (145.40%) is better than 100.00% of its industry peers.
- In the last couple of years the Gross Margin of ALPAT has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 34.16% | ||
| GM | 145.4% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.17%
GM growth 5Y-4.76%
2. Health
2.1 Basic Checks
- ALPAT does not have a ROIC to compare to the WACC, probably because it is not profitable.
- ALPAT has more shares outstanding than it did 1 year ago.
- The number of shares outstanding for ALPAT has been increased compared to 5 years ago.
- Compared to 1 year ago, ALPAT has an improved debt to assets ratio.
2.2 Solvency
- ALPAT has an Altman-Z score of 0.48. This is a bad value and indicates that ALPAT is not financially healthy and even has some risk of bankruptcy.
- Looking at the Altman-Z score, with a value of 0.48, ALPAT is in line with its industry, outperforming 58.14% of the companies in the same industry.
- ALPAT has a Debt/Equity ratio of 0.40. This is a healthy value indicating a solid balance between debt and equity.
- Looking at the Debt to Equity ratio, with a value of 0.40, ALPAT is in line with its industry, outperforming 56.98% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.4 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.48 |
ROIC/WACCN/A
WACC6.78%
2.3 Liquidity
- A Current Ratio of 0.88 indicates that ALPAT may have some problems paying its short term obligations.
- Looking at the Current ratio, with a value of 0.88, ALPAT is doing worse than 69.77% of the companies in the same industry.
- ALPAT has a Quick Ratio of 0.88. This is a bad value and indicates that ALPAT is not financially healthy enough and could expect problems in meeting its short term obligations.
- ALPAT has a worse Quick ratio (0.31) than 89.53% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.88 | ||
| Quick Ratio | 0.31 |
3. Growth
3.1 Past
- The earnings per share for ALPAT have decreased strongly by -73.00% in the last year.
- ALPAT shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -63.00%.
- Measured over the past years, ALPAT shows a quite strong growth in Revenue. The Revenue has been growing by 10.44% on average per year.
EPS 1Y (TTM)-73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-135.71%
Revenue 1Y (TTM)-63%
Revenue growth 3Y-5.79%
Revenue growth 5Y10.44%
Sales Q2Q%-86.85%
3.2 Future
- The Earnings Per Share is expected to grow by 68.40% on average over the next years. This is a very strong growth
- The Revenue is expected to grow by 31.88% on average over the next years. This is a very strong growth
EPS Next Y97.01%
EPS Next 2Y68.4%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year13.04%
Revenue Next 2Y31.88%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 28.44 indicates a quite expensive valuation of ALPAT.
- 79.07% of the companies in the same industry are more expensive than ALPAT, based on the Price/Earnings ratio.
- ALPAT is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 26.94, which is the current average of the S&P500 Index.
- With a Price/Forward Earnings ratio of 13.31, ALPAT is valued correctly.
- Based on the Price/Forward Earnings ratio, ALPAT is valued cheaper than 94.19% of the companies in the same industry.
- ALPAT is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 23.94, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 28.44 | ||
| Fwd PE | 13.31 |
4.2 Price Multiples
- 75.58% of the companies in the same industry are more expensive than ALPAT, based on the Enterprise Value to EBITDA ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 51.72 |
4.3 Compensation for Growth
- ALPAT's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- ALPAT's earnings are expected to grow with 68.40% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.29
PEG (5Y)N/A
EPS Next 2Y68.4%
EPS Next 3YN/A
5. Dividend
5.1 Amount
- ALPAT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
EPA:ALPAT (1/20/2026, 7:00:00 PM)
7.68
-0.1 (-1.29%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-29 2025-10-29
Earnings (Next)03-01 2026-03-01
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners33.62%
Ins Owner ChangeN/A
Market Cap8.60M
Revenue(TTM)936.80K
Net Income(TTM)320.00K
Analysts84.44
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 28.44 | ||
| Fwd PE | 13.31 | ||
| P/S | 9.18 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.88 | ||
| P/tB | 1.4 | ||
| EV/EBITDA | 51.72 |
EPS(TTM)0.27
EY3.52%
EPS(NY)0.58
Fwd EY7.51%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.84
BVpS8.71
TBVpS5.47
PEG (NY)0.29
PEG (5Y)N/A
Graham Number7.27
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2% | ||
| ROE | 3.43% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 34.16% | ||
| GM | 145.4% | ||
| FCFM | N/A |
ROA(3y)1.25%
ROA(5y)-1.47%
ROE(3y)2.03%
ROE(5y)-3.1%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.17%
GM growth 5Y-4.76%
F-ScoreN/A
Asset Turnover0.06
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.4 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 15.63 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.88 | ||
| Quick Ratio | 0.31 | ||
| Altman-Z | 0.48 |
F-ScoreN/A
WACC6.78%
ROIC/WACCN/A
Cap/Depr(3y)108.69%
Cap/Depr(5y)137.67%
Cap/Sales(3y)44.33%
Cap/Sales(5y)66.12%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-135.71%
EPS Next Y97.01%
EPS Next 2Y68.4%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-63%
Revenue growth 3Y-5.79%
Revenue growth 5Y10.44%
Sales Q2Q%-86.85%
Revenue Next Year13.04%
Revenue Next 2Y31.88%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-188.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year100%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y115.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y35.14%
OCF growth 3YN/A
OCF growth 5YN/A
PLANT ADVANCED TECHNOLOGIES / ALPAT.PA FAQ
Can you provide the ChartMill fundamental rating for PLANT ADVANCED TECHNOLOGIES?
ChartMill assigns a fundamental rating of 3 / 10 to ALPAT.PA.
What is the valuation status for ALPAT stock?
ChartMill assigns a valuation rating of 5 / 10 to PLANT ADVANCED TECHNOLOGIES (ALPAT.PA). This can be considered as Fairly Valued.
Can you provide the profitability details for PLANT ADVANCED TECHNOLOGIES?
PLANT ADVANCED TECHNOLOGIES (ALPAT.PA) has a profitability rating of 3 / 10.
What is the financial health of PLANT ADVANCED TECHNOLOGIES (ALPAT.PA) stock?
The financial health rating of PLANT ADVANCED TECHNOLOGIES (ALPAT.PA) is 1 / 10.